NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUPH shares have increased by 10.0% and is now trading at $15.51. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.05. The biotechnology company earned $0.03 million during the quarter, compared to analysts' expectations of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 40.66% and a negative net margin of 43,965.98%. View Aurinia Pharmaceuticals' earnings history.

9 equities research analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $23.75 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals.

Media headlines about AUPH stock have trended negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -2.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 4,200,000 shares, a decrease of 5.4% from the May 31st total of 4,440,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 3.0 days. Approximately 4.8% of the shares of the stock are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Some companies that are related to Aurinia Pharmaceuticals include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC) and Biohaven Pharmaceutical (BHVN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Alibaba Group (BABA), Exelixis (EXEL), Novavax (NVAX) and Corbus Pharmaceuticals (CRBP).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AUPH stock can currently be purchased for approximately $15.51.

Aurinia Pharmaceuticals has a market capitalization of $1.75 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]